Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Get Free Report)'s stock price passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $2.82 and traded as high as $2.84. Vistagen Therapeutics shares last traded at $2.77, with a volume of 206,572 shares.
Vistagen Therapeutics Stock Up 4.3 %
The company has a market cap of $83.99 million, a price-to-earnings ratio of -1.97 and a beta of 0.62. The business has a fifty day simple moving average of $2.81 and a 200 day simple moving average of $2.87.
Vistagen Therapeutics (NASDAQ:VTGN - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.02. Vistagen Therapeutics had a negative net margin of 6,777.08% and a negative return on equity of 48.12%. The firm had revenue of $230 billion during the quarter, compared to analysts' expectations of $0.18 million. Equities analysts anticipate that Vistagen Therapeutics, Inc. will post -1.77 EPS for the current fiscal year.
Institutional Investors Weigh In On Vistagen Therapeutics
Institutional investors have recently modified their holdings of the company. Stempoint Capital LP raised its holdings in Vistagen Therapeutics by 26.1% during the fourth quarter. Stempoint Capital LP now owns 2,328,492 shares of the company's stock worth $6,869,000 after purchasing an additional 481,700 shares during the last quarter. Nantahala Capital Management LLC increased its position in shares of Vistagen Therapeutics by 30.6% in the fourth quarter. Nantahala Capital Management LLC now owns 1,981,980 shares of the company's stock valued at $5,847,000 after buying an additional 464,284 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Vistagen Therapeutics by 4,826,425.0% during the 4th quarter. JPMorgan Chase & Co. now owns 772,244 shares of the company's stock worth $2,278,000 after buying an additional 772,228 shares during the last quarter. Almitas Capital LLC purchased a new stake in shares of Vistagen Therapeutics in the 4th quarter worth about $751,000. Finally, Two Sigma Investments LP grew its stake in Vistagen Therapeutics by 123.2% in the 4th quarter. Two Sigma Investments LP now owns 137,334 shares of the company's stock valued at $405,000 after acquiring an additional 75,792 shares during the last quarter. Hedge funds and other institutional investors own 78.39% of the company's stock.
About Vistagen Therapeutics
(
Get Free Report)
Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.
Read More
Before you consider Vistagen Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vistagen Therapeutics wasn't on the list.
While Vistagen Therapeutics currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
